Cargando…
Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
The prevalence of type 2 diabetes mellitus continues to increase in many Asian countries, with possible contributing factors, such as younger‐onset disease, diabetes development at lower body mass index, higher visceral fat accumulation and poorer β‐cell function, among Asian populations. Sodium–glu...
Autores principales: | Davidson, Jaime A, Sukor, Norlela, Hew, Fen‐Lee, Mohamed, Mafauzy, Hussein, Zanariah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889611/ https://www.ncbi.nlm.nih.gov/pubmed/36260389 http://dx.doi.org/10.1111/jdi.13915 |
Ejemplares similares
-
Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non‐Asians
por: Fujita, Yoshihito, et al.
Publicado: (2019) -
Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023) -
Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
por: Afzal, Muhammad, et al.
Publicado: (2021) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018) -
Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)